CD274 and neoplasm: ORR: 34.5% in PD-L1+ patients (prevalence: ~78%); 18.8% in PD-L1− patients; PD-L1+ cutoff: ≥1% tumor cells, detected by Merck anti-PD-L1 clone 78-10